Jagsonpal Pharmaceuticals (JAGSNPHARM) Q2 25/26 earnings summary

Executive summary

• H1 FY26 revenue grew 10% year-over-year to INR 1,501 million, with PAT up 39% to INR 234 million, reflecting strong execution and cost discipline.

• Q2 FY26 revenue was INR 745 million, remaining steady year-over-year due to GST transition, while PAT rose 10% to INR 126 million.

• Maintained robust cash reserves of INR 1,604 million after a 125% dividend payout.

• Leadership expanded with new COO and CFO to drive growth and operational excellence.

• Unaudited financial results for the quarter and half year ended 30 September 2025 were approved by the Board, with no material misstatements found by auditors.

Financial highlights

• H1 FY26 revenue from operations grew 10.2% year-over-year to INR 1,501 million; Q2 FY26 revenue was INR 745 million.

• H1 FY26 EBITDA (pre-ESOP) increased 8.8% year-over-year to INR 338 million; Q2 FY26 EBITDA was INR 181 million, margin at 24.3%.

• H1 FY26 PAT surged 39.2% year-over-year to INR 234 million; Q2 FY26 PAT was INR 126 million, up 10% year-over-year.

• Dividend payout enhanced to 125% in September 2025, totaling INR 166.58 million.

• Basic EPS for H1 FY26 was INR 3.48, compared to INR 2.52 for H1 FY25.

Outlook and guidance

• Expecting stronger performance in H2 FY26 as GST transition challenges subside and fundamentals remain strong.

• Targeting low double-digit (about 10%) revenue growth for FY26, with accelerated growth in subsequent years.

• Company continues to focus on pharmaceutical manufacturing and trading in India and overseas.